Presumed reduction of vestibular function in unilateral Menière's disease with aminoglycoside eardrops.
We report the first case in the world literature of deliberate ablation of vestibular function in unilateral Menière's disease with aminoglycoside eardrops (Garasone). These findings give conclusive proof that Garasone eardrops, and by implication, all topical aminoglycoside ear drops can be vestibulotoxic in the presence of a tympanic membrane defect. The lower concentration of gentamicin in Garasone, in comparison to the standard intratympanic preparations for chemical ablation of vestibular function, may also offer a reduction in the potential risk of cochleotoxocity.
Bath
A P
AP
Department of Otolaryngology, Toronto Hospital, Ontario, Canada.
Walsh
R M
RM
Bance
M L
ML
D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001623:Betamethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004338:Drug Combinations; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage* / Q000009:adverse effects; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007322:Instillation, Drug; D008575:Meniere Disease / Q000188:drug therapy*; D008875:Middle Aged; D014722:Vestibule, Labyrinth / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D005839:Gentamicins; D005938:Glucocorticoids; C028994:betamethasone sodium phosphate; D001623:Betamethasone